Association Between Serum Sirtuin-1 and Oxidative Stress Parameters in Type 2 Diabetic Patients

Ziad Tariq Taha; Arkan Tawfiq  Mohammad; Sara Abdullah  Kamil

doi:10.51699/cajmns.v7i2.3202

Authors

Ziad Tariq Taha Tikrit University, College of Basic Education/Al-Sharqat, Department of Science
Arkan Tawfiq Mohammad Tikrit University, College of Basic Education/Al-Sharqat, Department of Science
Sara Abdullah Kamil Tikrit University, College of Basic Education/Al-Sharqat, Department of Science

DOI:

https://doi.org/10.51699/cajmns.v7i2.3202

Keywords:

T2DM, Sirtuin 1, Oxidative Stress

Abstract

Samples were collected between October 2025 and January 2026. The study included 60 blood samples from patients diagnosed with Type 2 Diabetes Mellitus, including both males and females aged between 35 and 65 years. In addition, 30 blood samples were collected from apparently healthy individuals (males and females) aged between 35 and 55 years who served as the control group. All diabetic cases were clinically diagnosed by specialized physicians. The results showed a significant decrease in serum Sirtuin 1 (SIRT-1) levels in patients with type 2 diabetes mellitus (2.217±1.013 ng/mL) compared with the healthy control group (4.165±1.213 ng/mL) at a significance level of (P ≤ 0.01). Conversely, a significant increase was observed in oxidative stress markers, including Malondialdehyde (MDA) and the inflammatory chemokine CCL2, among diabetic patients compared with the control group at a highly significant level (P < 0.0001). In addition, the level of Hemoglobin A1c (HbA1c) was markedly elevated in patients compared with healthy individuals. The effect of Body Mass Index (BMI) was also evaluated, and the results indicated a significant increase in BMI among most diabetic patients compared with the control group, suggesting that increased body mass index may contribute to a higher risk of developing type 2 diabetes. Correlation analysis revealed a very weak positive relationship between SIRT-1 and oxidative stress markers, including MDA (r = 0.011) and CCL2 (r = 0.030). Furthermore, Receiver Operating Characteristic Curve (ROC) curve analysis was performed to evaluate the discriminative performance of the studied biomarkers in distinguishing diabetic patients from healthy individuals. The results demonstrated that HbA1c and BMI showed perfect discriminative accuracy, while SIRT-1 and oxidative stress markers exhibited very good to excellent diagnostic performance. Overall, these findings suggest that alterations in the balance of inflammatory and metabolic biomarkers, particularly the decrease in SIRT-1 and the elevation of oxidative stress and inflammatory markers, may play an important role in the progression and severity of type 2 diabetes mellitus.

References

E. Młynarska, W. Czarnik, N. Dzieża, W. Jędraszak, G. Majchrowicz, F. Prusinowski et al., “Type 2 diabetes mellitus new pathogenetic mechanisms, treatment and the most important complications,” International Journal of Molecular Sciences, vol. 26, no. 3, p. 1094, 2025.

GBD 2021 Diabetes Collaborators, “Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021,” The Lancet, vol. 402, pp. 203–234, 2023.

M. Strati, M. Moustaki, T. Psaltopoulou, A. Vryonidou, and S. A. Paschou, “Early onset type 2 diabetes mellitus: an update,” Endocrine, vol. 85, pp. 965–978, 2024.

A. Fedorczak, A. Lewiński, and R. Stawerska, “Sirtuin 1 serum concentration in healthy children: dependence on sex, age, stage of puberty, body weight and diet,” Frontiers in Endocrinology, vol. 15, p. 1356612, 2024.

M. C. Haigis and D. A. Sinclair, “Mammalian sirtuins: biological insights and disease relevance,” Annual Review of Pathology, vol. 5, pp. 253–295, 2010.

M. Kitada, Y. Ogura, I. Monno, and D. Koya, “Sirtuins and type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function,” Frontiers in Endocrinology, vol. 10, p. 187, 2019.

M. Kitada, Y. Ogura, and D. Koya, “The protective role of SIRT1 in diabetes and its complications,” Diabetes & Metabolism Journal, vol. 40, no. 3, pp. 187–194, 2016.

S. V. de Kreutzenberg et al., “SIRT1 and metabolic control: implications for insulin resistance,” Diabetes, vol. 59, no. 8, pp. 1876–1885, 2010.

A. Chalkiadaki and L. Guarente, “The multifaceted functions of sirtuins in cancer and metabolism,” Nature Reviews Cancer, vol. 15, pp. 608–624, 2015.

A. Ceriello and E. Motz, “Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 816–823, 2004.

H. Kanda et al., “MCP-1 contributes to macrophage infiltration into adipose tissue and insulin resistance in obesity,” Journal of Clinical Investigation, vol. 116, no. 6, pp. 1494–1505, 2006.

C. Herder, E. Dalmas, M. Böni-Schnetzler, and M. Y. Donath, “Role of cytokines and chemokines in the pathogenesis of type 2 diabetes,” Endocrine Reviews, vol. 38, no. 4, pp. 362–401, 2017.

R. Rahimi, S. Ghanbari, M. Khazaei, and E. Niroman, “Comparison of sirtuin 1 level and related blood factors in diabetic and healthy subjects,” Pediatric Endocrinology Diabetes and Metabolism, vol. 26, no. 1, pp. 17–21, 2020.

R. M. Azeez, W. K. Al-Hashemi, T. R. Al-Auqbi, and J. Jebali, “Relation of MDA as oxidative stress marker with lipid profile in diabetic patients,” Al-Nahrain Journal of Science, vol. 26, no. 3, pp. 12–17, 2023.

M. M. Mir et al., “The role of pro-inflammatory chemokines CCL-1, CCL-2, CCL-4, and CCL-5 in the etiopathogenesis of type 2 diabetes mellitus,” Journal of Personalized Medicine, vol. 14, p. 743, 2024.

H. Selvaraj et al., “Assessment of serum sirtuin 1 levels in type 2 diabetes mellitus with coronary artery disease patients,” Romanian Journal of Medical Practice, vol. 20, no. 3, p. 105, 2025.

M. Kitada and D. Koya, “SIRT1 in type 2 diabetes: mechanisms and therapeutic potential,” Diabetes & Metabolism Journal, vol. 37, pp. 315–325, 2013.

R. Yacoub, K. Lee, and J. C. He, “The role of SIRT1 in diabetic kidney disease,” Frontiers in Endocrinology, vol. 5, p. 166, 2014.

H. W. Liu and S. J. Chang, “Moderate exercise suppresses NF-κB signaling and activates the SIRT1-AMPK-PGC1α axis to attenuate muscle loss in diabetic db/db mice,” Frontiers in Physiology, vol. 9, p. 636, 2018.

Y. Cao et al., “SIRT1 and insulin resistance,” Journal of Diabetes and Its Complications, vol. 30, pp. 178–183, 2016.

B. Schwer and E. Verdin, “Conserved metabolic regulatory functions of sirtuins,” Cell Metabolism, vol. 7, pp. 104–112, 2008.

K. Türkmen, A. Karagoz, and A. Kucuk, “Sirtuins as novel players in the pathogenesis of diabetes mellitus,” World Journal of Diabetes, vol. 5, pp. 894–900, 2014.

A. Chalkiadaki and L. Guarente, “Sirtuins mediate mammalian metabolic responses to nutrient availability,” Nature Reviews Endocrinology, vol. 8, pp. 287–296, 2012.

V. Calabrese et al., “Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1822, pp. 729–736, 2012.

D. Chen and L. Guarente, “SIR2: a potential target for calorie restriction mimetics,” Trends in Molecular Medicine, vol. 13, pp. 64–71, 2007.

E. A. Khowailed et al., “Is the effect of caloric restriction on type 2 diabetes mellitus in rats mediated via sirtuin-1?” Medical Journal of Cairo University, vol. 83, pp. 357–365, 2015.

V. P. Jayasekharan et al., “Estimation of nitric oxide and malondialdehyde in serum and saliva of patients with oral lichen planus,” SRM Journal of Research in Dental Sciences, vol. 5, no. 4, p. 230, 2014.

M. W. A. Khan, K. Banga, and W. A. Khan, “Gluco-oxidation of proteins in the etiology of diabetic retinopathy,” in Diabetic Retinopathy, InTech, 2012, pp. 31–52.

M. Kumawat, “Antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus patients with and without nephropathy,” North American Journal of Medical Sciences, vol. 5, no. 3, p. 213, 2013.

N. Kurtul and E. Gökpınar, “Salivary lipid peroxidation and total sialic acid levels in smokers and smokeless tobacco users,” Mediators of Inflammation, vol. 2012, 2012.

Y. Yan et al., “Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population,” BMC Public Health, vol. 22, p. 1382, 2022.

M. M. Mir et al., “Differential association of selected adipocytokines with the pathogenesis and progression of type 2 diabetes mellitus,” Journal of Personalized Medicine, vol. 12, p. 735, 2022.

S. Harakeh et al., “Chemokines and their association with body mass index among healthy Saudis,” Saudi Journal of Biological Sciences, vol. 27, pp. 6–11, 2020.

G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature, vol. 444, pp. 860–867, 2006.

C. A. Feghali and T. M. Wright, “Cytokines in acute and chronic inflammation,” Frontiers in Bioscience, vol. 2, pp. d12–d26, 1997.

S. Purohit et al., “Large-scale discovery and validation studies demonstrate significant reductions in circulating levels of IL-8, IL-1Ra, MCP-1, and MIP-1β in subjects with type 1 diabetes,” Journal of Clinical Endocrinology & Metabolism, vol. 100, pp. E1179–E1187, 2015.